An older person with diabetes, hypertension, heart disease and chronic kidney impairment may leave one appointment with a new prescription, attend another specialist a week later and then be admitted to hospital after becoming dizzy, confused or dehydrated. Each individual medicine may have been prescribed for a defensible clinical reason. The risk emerges from what happens when several conditions, medicines and clinical decisions interact.
This is one of the defining challenges of later-life medicine. Multiple chronic conditions create legitimate demand for treatment, but the accumulation of disease-specific therapies can produce regimens that become difficult for patients, families and professionals to understand or manage safely. Within the wider Qatar Aging, Long-Term Care & Community Support system, polypharmacy therefore matters not simply as a pharmacy issue but as a test of how successfully the health system coordinates complex care around an older person.
Qatar already has important foundations. Primary Health Care Corporation provides family medicine, chronic-disease management, pharmacy services and multidisciplinary case management. Hamad Medical Corporation provides specialist geriatric care, a Medication Therapy Management Clinic at Rumailah Hospital, acute and urgent care for older people, home healthcare and post-discharge follow-up. The National Health Strategy 2024–2030 also places chronic care, healthy ageing, patient self-management, system integration, digital clinical quality and data integration within the national reform agenda.
The stronger opportunity is to make medication safety a continuous process rather than an occasional review: identifying what the person is actually taking, understanding why each medicine remains necessary, checking whether the combined regimen still matches the person’s health and function, and revisiting those decisions when circumstances change.
Multimorbidity changes the logic of treatment
Clinical guidelines are often organized around individual diseases. An older person does not experience their health that way.
A person may simultaneously live with diabetes, hypertension, ischemic heart disease, arthritis, chronic kidney disease and early cognitive impairment. Each condition can generate monitoring requirements, medicines, specialist appointments and lifestyle advice. The result is not merely six parallel care pathways. It is one person attempting to manage the combined consequences of all six.
The distinction matters because treatment recommendations can interact. A medicine intended to lower blood pressure may contribute to dizziness. Diuretic treatment may require monitoring of renal function and hydration. Pain treatment may interact with other medicines or affect cognition. Strict disease-specific targets may become less appropriate when frailty or limited life expectancy changes the balance between long-term preventive benefit and immediate treatment burden.
Multimorbidity therefore requires prioritization.
The clinical question is no longer only, “What is recommended for this condition?” It also becomes:
- Which conditions most affect the person’s current health and independence?
- Which treatments provide meaningful benefit within the person’s circumstances?
- Which medicines create overlapping or competing risks?
- How difficult is the regimen to follow accurately?
- What does the older person want treatment to achieve?
This shift connects Qatar’s aging agenda with the wider challenge of long-term conditions and chronic disease. The more conditions a person has, the more important it becomes to coordinate treatment around the individual rather than expecting the individual to coordinate a collection of disease pathways themselves.
Polypharmacy is not simply a high medicine count
Polypharmacy is sometimes treated as though taking many medicines is inherently inappropriate.
That is too simplistic.
An older person with several serious conditions may need numerous medicines, and reducing the number without understanding their purpose could cause substantial harm. The important distinction is between appropriate polypharmacy and a regimen that has accumulated medicines whose benefit, dose, interaction or continued necessity has not been sufficiently reconsidered.
HMC’s own healthy-ageing guidance recognizes this complexity. It encourages older people taking multiple medicines to seek medication review and advises them to maintain an up-to-date list of prescription and non-prescription treatments.
The practical risk is accumulation.
A medicine started during an acute episode may continue indefinitely. Another may be prescribed to manage a side effect of the first. Several specialists may legitimately focus on different clinical priorities. Over-the-counter products, supplements or herbal preparations may not appear immediately in the formal medication history.
Over time, nobody may have deliberately designed the final regimen as a whole.
That is why medication management and polypharmacy require periodic whole-regimen review rather than assessment of each prescription in isolation.
Primary care is the natural home for whole-person medication oversight
PHCC’s family medicine model gives Qatar an important structural advantage in managing multimorbidity.
Family physicians see patients across conditions rather than within a single specialty. PHCC pharmacy services operate across its health centers and include medication education, medication reconciliation, utilization review and medication optimization.
PHCC has also expanded Case Management Services across its health centers for patients with multiple chronic conditions and complex care needs. The model brings together multidisciplinary support around a personalized care plan and aims to improve continuity, self-management and coordination.
This is particularly relevant to older people whose health cannot be managed effectively through a sequence of unrelated consultations.
The strongest primary-care model has three functions.
First, it maintains visibility of the whole clinical picture. Second, it identifies where treatment plans from different specialties interact. Third, it provides continuity when no acute crisis is present.
That continuity matters because polypharmacy rarely becomes unsafe at a single moment. Risk often develops gradually as medicines, diagnoses and functional changes accumulate.
Scenario: six conditions, nine medicines and no single obvious error
A 74-year-old man attends PHCC with diabetes, hypertension, coronary artery disease, osteoarthritis, chronic kidney impairment and insomnia. He takes nine prescribed medicines and several supplements bought privately.
No individual prescription initially appears unreasonable.
However, the patient describes increasing fatigue and dizziness. He cannot explain the purpose of several tablets and sometimes skips his evening medicines because the regimen feels excessive.
A whole-person review changes the question. Rather than simply checking whether each disease is being treated, the family physician and pharmacist consider the complete medication list, recent blood results, renal function, blood pressure, symptoms, adherence and specialist recommendations.
The supplements are added to the medication history. Duplicated or unnecessary therapy can be identified if present. Medicines requiring dose adjustment or closer monitoring can be reviewed. The patient’s understanding of the regimen becomes part of the safety assessment.
The key governance insight is that nothing needed to be “wrongly prescribed” for the system to become unsafe. Complexity itself had become the risk.
Medication reconciliation protects the transitions where errors multiply
Medication lists are especially vulnerable when a person moves between services.
Admission to hospital, transfer between clinical teams and discharge back to the community can all produce discrepancies. One medicine may have been stopped but remain on an older list. A new treatment may be added without the previous version being removed. A dose may change. The person may continue taking medicines they already had at home alongside the newly supplied regimen.
Medication reconciliation is designed to reduce this risk by establishing the most accurate possible account of what the person actually takes and comparing that with the current clinical plan.
HMC monitors medication reconciliation as a patient-safety process in parts of its hospital system, while PHCC includes reconciliation within its pharmaceutical-care services.
For older people, reconciliation should include more than prescription records.
It needs to consider:
- prescribed medicines;
- medicines recently stopped or changed;
- over-the-counter products;
- herbal medicines and supplements;
- what the patient is actually taking rather than only what was prescribed; and
- who is responsible for communicating changes after transition.
This connects directly with hospital discharge and transitional care. A discharge summary can be clinically accurate yet still fail if the patient, family, PHCC team or home-health professional does not understand what changed.
Geriatric medicine can identify when disease-focused treatment becomes excessive
Geriatric medicine adds another layer because older people may experience medicine-related harm differently from younger adults.
Frailty, declining renal function, low body weight, cognitive change and altered pharmacological response can all change the balance between benefit and risk.
Rumailah Hospital’s geriatric services include a dedicated Medication Therapy Management Clinic. HMC has also established medication-management and deprescribing approaches within its age-friendly care work, bringing geriatricians and clinical pharmacists together for people with complex polypharmacy concerns.
This multidisciplinary structure is important.
The geriatrician can place medicines within the person’s overall health, prognosis, cognition and function. The clinical pharmacist can analyze the regimen in detail, including interactions, duplication, dosing and medication burden.
Together, they can ask a question that may be missed in a condition-specific clinic: does the total treatment plan still make sense for this person now?
Deprescribing is a clinical process, not a medicine-reduction target
Deprescribing is increasingly important in geriatric care, but it is easy to misunderstand.
It does not mean stopping medicines simply because an older person takes many of them.
It means systematically reviewing treatments and reducing or stopping a medicine when the potential harms, burden or lack of continuing benefit outweigh the reason for continuation.
Some medicines cannot be stopped abruptly. Some need dose reduction. Others remain essential even within a long regimen.
The decision therefore needs clinical ownership and monitoring.
Qatar-specific work within HMC’s Home Health Care Services has begun examining how older patients and caregivers view deprescribing. The findings are particularly useful because they challenge the assumption that patients inevitably resist reducing established treatment. The study found substantial willingness among participating patients and caregivers to stop one or more medicines where their physician recommended it, while also showing that many wanted involvement in those decisions.
This supports a person-centered model in which deprescribing is discussed rather than imposed.
The central message is not “fewer medicines are better.” It is “every medicine should continue to earn its place in the regimen.”
Shared decisions matter because medicine burden is lived at home
Clinicians see prescriptions. Patients experience routines.
An older person may need to remember tablets before food, after food, once daily, twice daily or at different times. Some medicines require monitoring. Others produce side effects that affect appetite, sleep, continence or mobility.
The practical burden can be considerable even when the clinical rationale is sound.
Patients therefore need understandable explanations of what each medicine is for, what benefits are expected, what adverse effects require attention and what should happen if a dose is missed.
HMC’s healthy-ageing guidance specifically encourages older people to keep a current medication list and to discuss side effects with doctors, nurses or pharmacists rather than stopping prescribed medicines independently.
This is also a health-literacy issue.
An effective medicine plan is not one the professional can explain. It is one the patient or responsible caregiver can use safely.
Where cognition, language, sensory impairment or complexity make that difficult, support should adapt accordingly.
Families can strengthen medication safety without becoming substitute clinicians
Families frequently play a substantial role in older-person care in Qatar.
A relative may collect medicines, organize appointments, prepare tablets, monitor symptoms and communicate with clinicians. For an older person with cognitive impairment or complex illness, that support can be essential.
But family involvement needs clear boundaries.
A caregiver should not be left to determine independently which medicines can be omitted when the person feels unwell. Nor should several relatives make different changes to the regimen because each believes they understand the treatment plan.
Medication safety improves when family involvement is structured:
- the older person remains involved to the greatest extent possible;
- one current medication list is maintained;
- changes are explained clearly;
- the family knows which symptoms require professional advice;
- professional responsibility for prescribing and review remains explicit.
The broader caregiver-support and navigation agenda is therefore highly relevant to polypharmacy. Families need information and access to advice, not simply additional responsibility.
Scenario: the daughter managing four specialist plans
An 81-year-old woman attends cardiology, endocrinology and geriatric clinics while also receiving routine primary care. Her daughter accompanies her to most appointments.
Over several months, doses are adjusted by different teams. The daughter keeps old medicine boxes at home “in case they are needed again.” She becomes uncertain whether one tablet was stopped permanently or only during an earlier illness.
The risk is not neglect. It is conscientious caregiving within a complex system.
A medication reconciliation establishes one current list. The purpose and dose of each medicine are explained. Superseded medication is clearly distinguished from active treatment. Where different specialties are involved, changes are visible to the clinicians responsible for continuing care.
The daughter’s role changes from trying to reconstruct clinical decisions herself to supporting a plan whose ownership is clear.
That distinction is critical. Family support should reduce risk, not become the mechanism through which fragmented professional information is repaired.
Kidney and liver function can change the safety of established treatment
A medicine that has been tolerated for years may become inappropriate at the same dose when physiology changes.
Renal function is particularly important because many medicines are eliminated through the kidneys. Older people with chronic kidney disease or acute dehydration can develop increased exposure to medicines that previously caused no problem.
Liver disease can similarly affect metabolism.
PHCC pharmacists and clinical teams have an important role in reviewing laboratory information and medicine use, while specialist pharmacists across HMC contribute to dosing and interaction decisions in more complex care.
This creates an important operational principle: medication safety requires current clinical information.
A medication list without recent renal function, relevant laboratory results or knowledge of acute illness may be insufficient for safe decision-making.
The problem becomes particularly important during infection, dehydration, reduced oral intake or acute deterioration. The regimen that was safe during stable chronic disease may need temporary or permanent adjustment.
Adverse effects can resemble aging itself
Some medicine-related problems are easy to recognize. A severe allergic reaction is obvious.
Others are much more subtle.
Dizziness, constipation, reduced appetite, fatigue, confusion or sleep disturbance may be attributed to old age or the underlying disease when treatment is contributing.
Medication review therefore needs to consider function as well as laboratory values.
Has the person become less steady since a medicine changed? Are they sleeping throughout the day? Has appetite declined? Has cognition worsened? Are they increasingly constipated? Have they stopped participating in normal activities?
These questions connect medication safety with quality and safety in aging services.
The medicine may be achieving its intended biochemical target while damaging the person’s ability to function.
The correct response is not automatically discontinuation. It is recognition that outcomes need to be interpreted through the whole person.
Polypharmacy is closely connected with falls and cognitive risk
Medication burden does not sit within a separate pharmacy pathway.
It intersects with other geriatric syndromes.
Sedation, dizziness and postural hypotension can contribute to falls. Anticholinergic burden can affect cognition and continence. Complex medicine routines can become harder to follow as memory deteriorates.
HMC’s Elderly Urgent Care Unit explicitly identifies polypharmacy alongside frailty, cognitive decline and limited mobility as part of the complexity encountered in older patients.
This is clinically significant because a new fall or episode of confusion should prompt consideration of medication as one possible contributor.
Medication review should therefore be triggered by changes in function, not only by annual routine.
A fall, delirium episode, unexplained deterioration, recurrent hospital attendance or transition into greater care dependency may all justify reassessment.
Urgent geriatric care can reduce the risk of fragmented treatment
Older people with multimorbidity often present with problems that do not fit neatly into one specialty.
The person may be weak, mildly confused, dehydrated and dizzy while also taking numerous medicines. A disease-specific response could treat the immediate symptom without examining the interactions between chronic illness, medication and function.
Rumailah Hospital’s Elderly Urgent Care Unit was designed around this complexity. It operates specifically for adults aged 60 and over and provides multidisciplinary geriatric assessment with access to pharmacists and other professionals.
The importance lies not merely in faster access.
An age-attuned urgent-care model can examine whether medication adjustment, frailty, cognition, mobility and caregiver circumstances are contributing to the presentation.
This can help reduce unnecessary admission while still identifying people who genuinely require hospital care.
Scenario: confusion after a “minor” illness
A 78-year-old man develops a respiratory infection and eats and drinks less for several days. His family then notices increasing confusion and instability.
He takes medicines for diabetes, blood pressure, heart disease and chronic pain.
The temptation is to treat the confusion as an inevitable consequence of infection.
A geriatric assessment looks wider. Hydration, renal function and medication exposure are reviewed alongside the acute illness. The team establishes whether reduced intake or physiological change has altered the safety of medicines that were previously tolerated.
Where clinically appropriate, treatment can be adjusted and monitored while the acute condition is managed.
The scenario demonstrates why medication safety cannot be separated from illness trajectory. Polypharmacy risk changes dynamically as the person’s condition changes.
Hospital discharge is one of the highest-risk medication moments
Acute hospital treatment frequently changes medication.
Some medicines are stopped. Others are temporarily withheld. New ones are introduced. Doses change in response to investigations or clinical deterioration.
Discharge therefore creates a critical handover.
HMC’s expanded Post-Discharge Follow-Up Program for older patients provides an important safety mechanism. Follow-up after discharge checks health status, access to medication, adherence to treatment and caregiver concerns.
For a person with polypharmacy, this early contact can identify practical problems that would otherwise remain hidden until the next scheduled appointment.
Does the patient actually possess the new medicine? Have they restarted a medicine that was meant to remain stopped? Do they understand the new dose? Are adverse effects emerging?
A strong transition closes these loops.
The wider principle is captured by closed-loop follow-up: the system should know not merely that information was sent, but that the next stage of care has received and acted upon what matters.
Home healthcare reveals whether medication plans work in real life
Home healthcare provides a different perspective from clinic care.
Professionals can see how medicines are actually stored, organized and administered. They may discover duplicate supplies, outdated boxes, confusing routines or significant caregiver dependence that was not apparent during a hospital consultation.
HMC’s Home Health Care Services include clinical pharmacy expertise and have undertaken work on medication management, deprescribing and transition of care among older home-care patients.
This makes the home a valuable medication-safety environment rather than simply a place where prescriptions are consumed.
The strongest home-based approach can identify discrepancies early, reinforce patient and caregiver education, communicate concerns to prescribers and support review where the regimen has become burdensome or unsafe.
Digital records can reduce fragmentation, but data still require interpretation
Qatar’s investment in connected digital healthcare provides an important foundation for multimorbidity management.
Shared clinical information can make prescriptions, laboratory results and treatment histories more visible across the healthcare system. The National Health Strategy 2024–2030 places data integration, digitally enhanced clinical quality and digitally empowered patients within the national reform program.
But interoperability alone does not solve polypharmacy.
A digital record can show that ten medicines are active. It cannot automatically determine whether all ten remain appropriate for the person.
Digital systems need to support clinical judgment through accurate medication histories, interaction warnings, visibility of recent changes, monitoring prompts and clear responsibility for reconciliation.
They also need strong information governance.
Organizations examining comparable digital medication pathways can use the Digital Transformation, AI and Cybersecurity Readiness Assessment to test whether technology, workflow, governance and clinical safety are developing together.
The purpose is not to automate prescribing decisions. It is to make safer decision-making easier.
Medication governance needs clear ownership
Complex medication regimens expose one of the central governance problems in integrated care: several professionals may influence treatment while no single professional appears to own the complete regimen.
The relevant actors can include PHCC family physicians, HMC specialists, geriatricians, hospital pharmacists, PHCC pharmacists, home-health teams and private providers.
Each may control only part of the pathway.
A safer model therefore needs clarity over who reconciles, who reviews and who follows up.
Responsibility may legitimately shift as the person moves between settings. What matters is that the shift is visible.
For example, hospital clinicians may alter treatment during admission, but the long-term regimen may subsequently return to primary-care oversight. A geriatric Medication Therapy Management Clinic may recommend deprescribing, while the family physician supports ongoing monitoring. A specialist may need to retain responsibility for a medicine requiring condition-specific surveillance.
Governance should make these relationships explicit rather than assuming that shared records automatically create shared accountability.
The Governance Maturity Assessment can help organizations examining similar multi-provider pathways test whether ownership, escalation and assurance remain visible as care becomes more complex.
Medication safety needs outcomes beyond dispensing accuracy
Traditional medication-safety measures often focus appropriately on prescribing errors, dispensing errors and reconciliation compliance.
Those remain important.
For older people with multimorbidity, however, the outcome framework should extend further.
A mature system should also be able to examine whether medication management affects:
- adverse drug events;
- falls and delirium;
- avoidable hospital attendance;
- functional decline;
- patient understanding and adherence;
- medicine burden and treatment acceptability; and
- successful medication reconciliation after care transitions.
This links polypharmacy to the wider outcomes-frameworks and indicators agenda.
A service that performs large numbers of medication reviews has demonstrated activity. It has not yet demonstrated impact.
Decision-makers need to know whether those reviews prevented harm, simplified inappropriate complexity, improved adherence or allowed people to remain healthier and more independent.
The Quality Dashboard Builder offers a practical way for organizations examining comparable systems to connect medication-safety process measures with outcome and service-performance indicators.
Deprescribing needs follow-through as carefully as prescribing
Stopping a medicine can itself create risk if the process is poorly managed.
Some treatments need gradual reduction. Withdrawal effects may require monitoring. Symptoms may reappear. Patients who have taken a medicine for many years may feel anxious when it is removed.
A defensible deprescribing process therefore includes a clinical rationale, communication with the patient and caregiver, monitoring arrangements and clarity over what happens if symptoms recur.
This is particularly important when several clinicians are involved.
A medicine discontinued by one service should not be unintentionally restarted by another because an older list remains visible or because the rationale was not communicated.
Deprescribing therefore needs the same discipline as initiating treatment.
The purpose is not simply to reduce prescribing volume. It is to improve the relationship between treatment, health outcomes and the priorities of the older person.
Scenario: deciding whether a long-standing medicine still adds value
An 86-year-old woman with frailty, reduced appetite and increasing dependency takes a preventive medicine that was started many years earlier.
The treatment was entirely reasonable when prescribed. Her health circumstances are now different.
Rather than continuing it automatically because it appears on the medication list, the geriatric team reviews its likely benefit, current risks, treatment burden and the woman’s priorities.
The decision may still be to continue. If the balance has changed, supervised deprescribing may be appropriate.
The important control is that the decision is deliberate.
The clinical team discusses the reasoning with the woman and her family, records the plan, communicates it to the professionals continuing her care and establishes monitoring where needed.
This is what person-centered polypharmacy management looks like: not automatic continuation and not automatic reduction, but treatment that remains connected to current goals.
Financial and system value come from preventing treatment-related harm
Polypharmacy has a financial dimension, but the strongest economic argument is not simply that fewer medicines cost less.
Stopping beneficial medicines purely to reduce expenditure would be poor care.
The more important value lies in avoiding the downstream costs associated with preventable medication harm.
Adverse drug events can generate emergency attendance, diagnostic investigation, hospital admission, falls, fractures and prolonged rehabilitation. Poor adherence to an excessively complicated regimen can also destabilize chronic disease and generate avoidable healthcare demand.
This places medication management within the wider avoidable-utilization governance discussion.
Better medication review may require more clinical time upfront, including pharmacists, physicians and geriatric expertise. That does not make it inefficient.
The correct value question is whether targeted review reduces harm and helps people remain stable enough to avoid more intensive care.
Workforce capability is as important as medication technology
Safe polypharmacy management requires a workforce able to operate beyond professional silos.
Family physicians need confidence managing multimorbidity rather than simply referring every individual condition onward. Specialist clinicians need visibility of how their treatment interacts with the wider regimen. Pharmacists need access to the clinical information required for meaningful medication optimization. Nurses and home-health professionals need to recognize medicine-related deterioration and escalate concerns appropriately.
Geriatric expertise becomes especially important when frailty, cognition and functional decline change the treatment balance.
This is not only a question of increasing staffing.
It is also about workforce capability and skill mix: using the complementary expertise of physicians, pharmacists, nurses and allied professionals to manage complexity more safely.
Qatar’s relatively integrated public health infrastructure gives it an opportunity to strengthen these collaborative models before the older population becomes substantially larger.
Stronger population data can show where medication burden is concentrating
At system level, Qatar will increasingly need to understand not only how many older people live with chronic disease but how those conditions combine.
Population-level multimorbidity data can inform workforce planning, pharmacy demand, specialist geriatric capacity and preventive strategy.
Medication data can add another layer.
Useful analysis might examine the proportion of older people taking high numbers of medicines, use of medicines associated with particular geriatric risks, frequency of medication review, discrepancies identified at transitions and patterns of adverse drug events.
The purpose should not be to label all high medicine counts as poor practice.
Data should identify where complexity is greatest and where closer review may provide most value.
This connects directly with data collection and data quality. Poor medication data can create false assurance just as easily as insufficient data.
Future care should become increasingly personalized around treatment burden
As Qatar’s aging population grows, multimorbidity will become a more prominent organizing challenge for healthcare.
The likely future direction is not disease-specific medicine disappearing. Specialist expertise will remain essential.
The change is that treatment plans will need to become more explicitly personalized around combinations of disease, function, cognition, frailty and patient preference.
Digital decision support may help identify interactions, duplication and monitoring gaps. Pharmacogenomic and precision-medicine approaches may eventually improve treatment selection in some areas. Artificial intelligence may support clinical review by identifying patterns that are difficult to recognize manually.
These tools should remain supportive rather than determinative.
Older-person medication decisions involve values as well as calculations. A system can estimate risk, but it cannot decide automatically how a person values longevity, symptom control, independence, treatment burden or cognitive clarity.
That judgment remains fundamentally human.
What Qatar’s experience offers internationally
Qatar’s institutional structure differs from many larger healthcare systems. PHCC provides a coordinated national primary-care platform, while HMC holds a major role in public hospital, specialist, geriatric and home healthcare. This creates integration opportunities that may be harder to achieve in highly fragmented insurance or provider markets.
The structural model therefore cannot simply be copied.
Several principles are more transferable.
The first is that multimorbidity should be treated as a clinical reality in its own right rather than as the accidental overlap of individual disease programs.
The second is that pharmacists need to be integrated into care rather than positioned only at the point of medicine supply.
The third is that medication reconciliation should be treated as a transition control, not an administrative exercise.
The fourth is that deprescribing is strongest when it is clinically supervised, person-centered and linked to follow-up.
And the fifth is that medication safety should be evaluated through health, function and quality of life as well as prescribing accuracy.
The transferable lesson lies less in Qatar’s precise institutional arrangements and more in the principle that complex treatment needs active coordination. No health system should assume that a collection of individually reasonable prescriptions automatically becomes a reasonable overall medication plan.
Conclusion
Multiple chronic conditions and polypharmacy will become increasingly important within Qatar’s aging agenda because successful treatment itself creates complexity. Older people may live longer with diabetes, cardiovascular disease, kidney impairment, musculoskeletal conditions and other chronic illnesses, while accumulating medicines and specialist relationships across the course of that care.
Qatar already has important foundations for managing this safely: PHCC family medicine and case management, multidisciplinary pharmacy services, HMC geriatric care, Medication Therapy Management, Elderly Urgent Care, medication reconciliation, home healthcare and post-discharge follow-up.
The central challenge is to make those capabilities operate as one continuous medication-safety system.
That means knowing what the person is actually taking, reviewing whether every medicine still provides sufficient benefit, considering renal function, cognition and frailty, involving patients and caregivers in decisions, reconciling treatment at transitions and making professional ownership visible when several services are involved.
The strongest future model will not judge quality by medicine count alone. It will ask whether the complete regimen remains safe, understandable, proportionate and aligned with what the older person is trying to preserve.
For Qatar, this is ultimately a question of healthy aging as much as prescribing. Medicines should help people live longer and better; the system’s task is to ensure that the complexity created by treatment does not begin to undermine the independence, function and quality of life that treatment was intended to protect.